Skip to Main Content

An official website of the United States government

Association Between Aspirin Use and Risk of Liver Carcinoma: Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and a meta-analysis of 4 cohort studies

Principal Investigator
Name
Xuesi Dong
Degrees
Ph.D
Institution
Nanjing Medical University
Position Title
None
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-419
Initial CDAS Request Approval
Nov 5, 2018
Title
Association Between Aspirin Use and Risk of Liver Carcinoma: Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and a meta-analysis of 4 cohort studies
Summary
A body of experimental and epidemiologic evidence suggests that aspirin may prevent incident liver cancer (LC) via inhibition of the proinflammatory cyclooxygenase-2 (COX-2) enzyme. However, to date, the study on optimal aspirin dosage and duration of use for chemoprevention remain limited. We aim to examine the potential benefits of aspirin use for primary LC prevention at a range of doses and durations of use within PLCO dataset, and conduct an systemic-meta analysis among related cohort studies. In this study, I will adjust some important covariates, e.g: dietary and vitamin D, to balance some potential bias.
Aims

Investigate the potential benefits of aspirin use for primary LC prevention at a range of doses and durations of use within PLCO dataset.

Collaborators

None

Related Publications